Carolynne J Vaizey1, Peter R Gibson2, Christopher M Black3,4, Rebecca J Nicholls5, Adèle R Weston5, Daniel R Gaya6, Shaji Sebastian7, Ian Shaw8, Stephen Lewis9, Stuart Bloom10, John N Gordon11, Amanda Beale12, Ian Arnott13, Simon Campbell14, Tao Fan4. 1. Department of Surgery, St. Mark's Hospital, London, UK. 2. Alfred Hospital, Melbourne, and Monash University, Victoria, Australia. 3. St. John's University, Queens, New York, USA. 4. Merck & Co., Inc., Global Health Outcomes, Whitehouse Station, New Jersey, USA. 5. OptumInsight, Sydney, Australia. 6. Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, UK. 7. Department of Gastroenterology, Hull Royal Infirmary, Hull, UK. 8. Department of Gastroenterology, Gloucester Royal Hospital, Gloucester, UK. 9. Department of Gastroenterology, Derriford Hospital, Plymouth, UK. 10. Department of Gastroenterology, University College London Hospital, London, UK. 11. Department of Gastroenterology, Royal Hampshire Hospital, Winchester, UK. 12. Bristol Royal Infirmary, Bristol, UK. 13. Western General Hospital, Edinburgh, UK. 14. Manchester Royal Infirmary, Manchester, UK.
Abstract
BACKGROUND: Ulcerative colitis is a lifelong, chronic, relapsing-remitting disease. OBJECTIVE: To assess the relationship between ulcerative colitis disease status and patient quality of life, and to determine the impact of ulcerative colitis on healthcare costs and work productivity, in the UK. METHODS: Clinicians assessed 173 adult patients' current disease status at a single study visit using the partial Mayo (pMayo) instrument. Patients completed the Euro Quality of Life 5-dimension, 5-level (EQ-5D-5L) questionnaire, the Work Productivity and Activity Impairment (WPAI) questionnaire. Healthcare resource use was determined from questionnaires and from patients' medical charts. RESULTS: Patients in remission had a significantly higher EQ-5D-5L scores (mean (SD) 0.86 (0.15)) than patients with active disease (0.71 (0.20); p<0.001). Patients with mild disease had significantly higher mean (SD) EQ-5D-5L scores than patients with moderate/severe disease: 0.77 (0.11) and 0.66 (0.24), respectively (p<0.001). The mean percent productivity impairment was greater for patients with active disease than for patients in remission on all items of the WPAI questionnaire: 24.6% vs 1.8% for work time missed, 34.1% vs 12.9% for impairment while working, 40.8% vs 14.4% for overall work impairment and 42.7% vs 13.0% for activity impairment (p<0.001 for all comparisons). The mean (SD) total cost of healthcare for ulcerative colitis in the prior 3 months was £1211 (1588). CONCLUSIONS: When compared with patients in remission, patients with active ulcerative colitis have significantly worse quality of life and significantly more work impairment. The healthcare costs of ulcerative colitis are considerable.
BACKGROUND:Ulcerative colitis is a lifelong, chronic, relapsing-remitting disease. OBJECTIVE: To assess the relationship between ulcerative colitis disease status and patient quality of life, and to determine the impact of ulcerative colitis on healthcare costs and work productivity, in the UK. METHODS: Clinicians assessed 173 adult patients' current disease status at a single study visit using the partial Mayo (pMayo) instrument. Patients completed the Euro Quality of Life 5-dimension, 5-level (EQ-5D-5L) questionnaire, the Work Productivity and Activity Impairment (WPAI) questionnaire. Healthcare resource use was determined from questionnaires and from patients' medical charts. RESULTS:Patients in remission had a significantly higher EQ-5D-5L scores (mean (SD) 0.86 (0.15)) than patients with active disease (0.71 (0.20); p<0.001). Patients with mild disease had significantly higher mean (SD) EQ-5D-5L scores than patients with moderate/severe disease: 0.77 (0.11) and 0.66 (0.24), respectively (p<0.001). The mean percent productivity impairment was greater for patients with active disease than for patients in remission on all items of the WPAI questionnaire: 24.6% vs 1.8% for work time missed, 34.1% vs 12.9% for impairment while working, 40.8% vs 14.4% for overall work impairment and 42.7% vs 13.0% for activity impairment (p<0.001 for all comparisons). The mean (SD) total cost of healthcare for ulcerative colitis in the prior 3 months was £1211 (1588). CONCLUSIONS: When compared with patients in remission, patients with active ulcerative colitis have significantly worse quality of life and significantly more work impairment. The healthcare costs of ulcerative colitis are considerable.
Entities:
Keywords:
HEALTH SERVICE RESEARCH; QUALITY OF LIFE; ULCERATIVE COLITIS
Authors: James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg Journal: Inflamm Bowel Dis Date: 2008-12 Impact factor: 5.325
Authors: Christoph Lohan; Alex Diamantopoulos; Corinne LeReun; Emily Wright; Natalie Bohm; Laura Marie Sawyer Journal: BMJ Open Gastroenterol Date: 2019-07-30
Authors: Alessandro Armuzzi; Miriam Tarallo; James Lucas; Daniel Bluff; Benjamin Hoskin; Danielle Bargo; Joseph C Cappelleri; Leonardo Salese; Marco daCosta DiBonaventura Journal: BMC Gastroenterol Date: 2020-01-21 Impact factor: 3.067
Authors: Matthew J Brookes; John Waller; Joseph C Cappelleri; Irene Modesto; Marco D DiBonaventura; Natalie Bohm; Ruth Mokgokong; Olivia Massey; Robert Wood; Danielle Bargo Journal: BMJ Open Gastroenterol Date: 2020-09